Cargando…
Pembrolizumab-Induced Adrenal Insufficiency Presenting Eight Months After Cessation of Treatment
Pembrolizumab is a monoclonal antibody that functions as an immune checkpoint inhibitor. It is an FDA-approved immunotherapy used to treat various malignancies. With its wide use in cancer therapy, there are many known side effects. It is a common cause of endocrinopathies such as thyroid disease an...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Cureus
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10374333/ https://www.ncbi.nlm.nih.gov/pubmed/37519548 http://dx.doi.org/10.7759/cureus.41049 |